Health, HIV, Social Security, Disability Insurance
Working Papers Series
Economics | Health Policy | Public Affairs, Public Policy and Public Administration | Social Welfare
This study examines the effect of health on SSDI outcomes. The effect is identified by a new antiretroviral therapy to treat the human immunodeficiency virus. Administrative data on SSDI applications come from the Disability Research File. According to the analysis, the new therapy had an immediate and persistent effect on program entry. By 1997, the therapy decreased applications by 35.2 percent and new awards by 36.7 percent. Among existing beneficiaries, the therapy decreased program exits through death, but did not substantially increase program exits for work. By 1999, the therapy increased HIV-related expenditures by $43.6 million.
Singleton, Perry, "Health, Medical Innovation and Disability Insurance: A Case Study of HIV Antiretroviral Therapy" (2015). Center for Policy Research. 210.
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.